Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas
暂无分享,去创建一个
Horst Buerger | Eberhard Korsching | Carsten Gebert | Georg Gosheger | Konstantin Agelopoulos | Uta Dirksen | U. Dirksen | S. Bielack | B. Brandt | G. Gosheger | H. Buerger | H. Juergens | K. Agelopoulos | Burkhard Brandt | Hartmut Schmidt | H. Schmidt | Christian Kersting | Christian August | Heribert Juergens | Wilfried Winkelmann | Stefan Bielack | E. Korsching | C. Gebert | C. August | C. Kersting | W. Winkelmann
[1] B. Brandt,et al. Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response , 2006, Clinical Cancer Research.
[2] S. Knuutila,et al. Gene amplifications in osteosarcoma—CGH microarray analysis , 2005, Genes, chromosomes & cancer.
[3] E. van Marck,et al. Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. , 2002, European journal of cancer.
[4] Manuel Hidalgo,et al. An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors , 2004, Cancer Research.
[5] C. Liedtke,et al. Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression , 2006, Laboratory Investigation.
[6] J. Isola,et al. Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence—first results of an inter‐ethnic breast cancer study , 2004, The Journal of pathology.
[7] W. Winkelmann,et al. Genetic imbalances revealed by comparative genomic hybridization in osteosarcomas , 2002, International journal of cancer.
[8] S. Groshen,et al. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] S. Leenstra,et al. Malignant astrocytoma‐derived region of common amplification in chromosomal band 17p12 is frequently amplified in high‐grade osteosarcomas , 1997, Genes, chromosomes & cancer.
[10] Ge Zhang,et al. Statistical power of association using the extreme discordant phenotype design , 2006, Pharmacogenetics and genomics.
[11] K. Straif,et al. Modification of Breast Cancer Risk in Young Women by a Polymorphic Sequence in the egfr Gene , 2004, Cancer Research.
[12] K. Zänker,et al. Modulation of Epidermal Growth Factor Receptor Gene Transcription by a Polymorphic Dinucleotide Repeat in Intron 1* , 1999, The Journal of Biological Chemistry.
[13] G. Delling,et al. Morphological grades of regression in osteosarcoma after polychemotherapy — Study COSS 80 , 2004, Journal of Cancer Research and Clinical Oncology.
[14] O. Kallioniemi,et al. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. , 2000, Cancer genetics and cytogenetics.
[15] S. Groshen,et al. Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer. , 2005, Clinical colorectal cancer.
[16] W. Winkelmann,et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Simon,et al. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. , 2000, Cancer research.
[18] S. Knuutila,et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. , 1995, Cancer research.
[19] C. Liedtke,et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma , 2004, Laboratory Investigation.
[20] P. V. van Diest,et al. Pitfalls in immunohistochemical assessment of EGFR expression in soft tissue sarcomas , 2006, Journal of Clinical Pathology.
[21] S. Groshen,et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab , 2006, Pharmacogenetics and genomics.
[22] W. Winkelmann,et al. Epidermal Growth Factor Receptor Expression in High-Grade Osteosarcomas Is Associated with a Good Clinical Outcome , 2007, Clinical Cancer Research.
[23] S. Knuutila,et al. Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma. , 2002, Cancer genetics and cytogenetics.
[24] S. Knuutila,et al. Amplification of 17p11.2∼p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma , 2002 .
[25] T. Giordano,et al. Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma , 2004, Cancer Research.
[26] M. Hidalgo,et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Bielack,et al. Surgical expertise and outcome in osteosarcoma trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] K. Radig,et al. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. , 1995, General & diagnostic pathology.
[29] S. Bielack,et al. Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.